This website uses cookies to offer you the best possible user experience. Cookies’ information is stored in your browser and performs functions such as recognizing when you return to our website or helping our team to understand which sections of the website you find most interesting and useful. More information in the privacy policy and cookie policy!
Labiana |
15 December
Se trata de un anti-inflamatorio que puede prescribirse como coadyuvante en el tratamiento de enfermedades que cursen con dolor e inflamación en bovino, porcino, perros y gatos. Su principio activo es el ácido tolfenámico
LABIANA REACHES THE FINAL STAGES OF ITS IPO AND MARKS A MILESTONE IN THE SPANISH VETERINARY INDUSTRY
Labiana |
23 May
Labiana Health S.A. ("Labiana" or the "Group") is an integrated and independent animal and human health platform with international presence,
Labiana |
12 May
One of the main products we developed within our strategic plan of organic growth. We invested in purchasing new assets,
Labiana |
22 October
From Labiana Pharmaceuticals we are proud to announce the expansion of our production facilities with a new line for liquid ampoules
Labiana |
28 September
After almost 2 years of virtual exhibitions, Labiana team is keen to see you again at the main pharmaceutical and
Labiana |
9 June
Introduction Myxomatosis is a widespread and lethal viral disease of the common rabbit (Oryctolagus cuniculus) caused by the Myxoma virus